Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent.
作者信息
YU T F, PATON B C, CHENKIN T, BURNS J J, BRODIE B B, GUTMAN A B
出版信息
J Clin Invest. 1956 Apr;35(4):374-85. doi: 10.1172/JCI103288.
Abstract
摘要
相似文献
1
Effect of a phenylbutazone analog (4-[phenylthioethyl]-1, 2-diphenyl 3, 5-pyrazolidinedione) on urate clearance and other discrete renal functions in gouty subjects; evaluation as uricosuric agent.
J Clin Invest. 1956 Apr;35(4):374-85. doi: 10.1172/JCI103288.
2
Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects.
J Clin Invest. 1953 Nov;32(11):1121-32. doi: 10.1172/JCI102836.
3
Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects.
Arthritis Rheum. 1958 Dec;1(6):532-43. doi: 10.1002/art.1780010606.
4
5
Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione).
Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):884-7. doi: 10.3181/00379727-86-21263.
6
[CASE OF CHRONIC TOPHOCEOUS GOUT].
Iryo. 1963 Dec;17:736-40.
7
[Early results of the action of a new uricosuric agent, G. 28315, and study of renal tolerance of it].
Rhumatologie. 1960 Jan-Feb;12:15-25.
8
Uricosuric agents in the management of chronic tophaceous gout with renal impairment.
N Z Med J. 1961 Aug;60:390-2.
9
[Therapeutic agents for gout effecting the kidney].
Geka Chiryo. 1970 Mar;22(3):317-22.
10
Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis.
Trans Assoc Am Physicians. 1951;64:279-88.
引用本文的文献
1
Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.
J Clin Invest. 1959 Aug;38(8):1298-315. doi: 10.1172/JCI103905.
2
Renal regulation of uric acid excretion in normal and gouty man; modification by uricosuric agents.
Bull N Y Acad Med. 1958 May;34(5):287-96.
3
Evaluation of uricosuric agents in chronic gout.
Ann Rheum Dis. 1957 Dec;16(4):425-37. doi: 10.1136/ard.16.4.425.
本文引用的文献
1
Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects.
J Clin Invest. 1952 Jul;31(7):692-701. doi: 10.1172/JCI102651.
2
The metabolic fate of phenylbutazone (butazolidin) in man.
J Pharmacol Exp Ther. 1955 Apr;113(4):481-9.
3
Paradoxical retention of uric acid by uricosuric drugs in low dosage.
Proc Soc Exp Biol Med. 1955 Nov;90(2):542-7. doi: 10.3181/00379727-90-22094.
4
The effect of phenylbutazone on uric acid metabolism in two normal subjects.
J Clin Invest. 1955 Feb;34(2):256-62. doi: 10.1172/JCI103078.
5
Further observation on the uricosuric effects of probenecid (benemid) in tophaceous gout.
Trans Assoc Am Physicians. 1954;67:250-60.
6
Observations on G-25671, a phenylbutazone analogue (4-phenylthioethyl)-1,2-diphenyl 3,5-pyrazolidinedione).
Proc Soc Exp Biol Med. 1954 Aug-Sep;86(4):884-7. doi: 10.3181/00379727-86-21263.
7
Phenylbutazone (butazolidin) in gout.
Am J Med. 1954 Feb;16(2):212-7. doi: 10.1016/0002-9343(54)90336-8.
8
Ultrafiltrability of plasma urate in man.
Proc Soc Exp Biol Med. 1953 Oct;84(1):21-4. doi: 10.3181/00379727-84-20528.
9
The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material.
J Pharmacol Exp Ther. 1953 Nov;109(3):346-57.
10
Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects.
J Clin Invest. 1953 Nov;32(11):1121-32. doi: 10.1172/JCI102836.
Zotero 插件